{"id":"W2768057131","doi":"10.1093/neuonc/nox168.058","title":"ACTR-71. FULL ENROLLMENT RESULTS FROM THE PHASE 1/2, MULTICENTER, OPEN-LABEL STUDY OF MARIZOMIB (MRZ) ± BEVACIZUMAB (BEV) IN RECURRENT WHO GRADE IV MALIGNANT GLIOMA (GLIOBLASTOMA, RGBM)","year":2017,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Glioma; Lethargy; Bevacizumab; Adverse effect; Internal medicine; Phases of clinical research; Surgery; Gastroenterology; Toxicity; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007349506,0.0005427474,0.001396766,0.0002597758,0.0004122604,0.0001468021,0.001340461,0.0002495599,0.00007814341],"category_scores_gemma":[0.0009989243,0.0003730566,0.0001518426,0.000240204,0.0002466778,0.0002161801,0.001202417,0.0005889944,0.00005431656],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004998342,"about_ca_system_score_gemma":0.0002722795,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002849211,"about_ca_topic_score_gemma":0.006190776,"domain_scores_codex":[0.9953774,0.0007139951,0.001369801,0.001187996,0.0006262765,0.0007245065],"domain_scores_gemma":[0.9947464,0.001321506,0.001158207,0.002271219,0.0001737111,0.000328921],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.0763161,0.1993635,0.02479103,0.00006641356,0.001216734,0.01512444,0.01071334,0.00001285561,0.4603231,0.0001040604,0.01632519,0.1956433],"study_design_scores_gemma":[0.6167019,0.09160347,0.08548096,0.000746247,0.001710999,0.0002884448,0.003789814,0.00201935,0.1167243,0.0001306113,0.07996746,0.0008363973],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9811778,0.0003909405,0.000001380548,0.0113762,0.00130043,0.004701477,0.000366157,0.000036626,0.0006489609],"genre_scores_gemma":[0.9977978,0.0003606176,0.0001497037,0.0006828398,0.000214095,0.0006352864,0.00007239247,0.00006194346,0.00002535198],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5403858,"threshold_uncertainty_score":0.9998721,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0698189916436657,"score_gpt":0.3799224895923255,"score_spread":0.3101034979486598,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}